coLucid.com
About coLucid.com
CoLucid Pharmaceuticals was founded in December 2005 by Pappas Ventures to advance innovative drug candidates with the potential to provide safe and effective treatment of central nervous system (CNS) disorders. Lead Product Candidate Our lead compound, COL-144, is a first in class Neurally Acting Anti-Migraine Agent (NAAMA) designed to deliver efficacy in migraine without the vasoconstrictor activity associated with previous generations of migraine therapy.
